Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fennec Pharmaceuticals (FENC)
NASDAQ:FENC
RESEARCH TOOLSreports
Fennec Pharmaceuticals (FENC) Stock Price & Analysis
206 Followers
FENC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.66 - $11.92
Previous Close$6.39
Volume37.75K
Average Volume (3M)146.73K
Market Cap
$175.94M
Enterprise Value$192.40M
Total Cash (Recent Filing)$13.27M
Total Debt (Recent Filing)$29.73M
Price to Earnings (P/E)172.7
Beta0.11
Next Earnings
Aug 09, 2024EPS Estimate
-$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding27,105,000
10 Day Avg. Volume96,409
30 Day Avg. Volume146,730
Standard Deviation0.15
R-Squared0.01
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-15.28
Price to Sales (P/S)17.88
Price to Cash Flow (P/CF)-9.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.05
Enterprise Value/Gross Profit9.62
Enterprise Value/Ebitda-15.56
Forecast
1Y Price Target
$18.00Price Target Upside173.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Fennec Pharmaceuticals News
PremiumCompany Announcements
Adrian Haigh Exits as COO of Fennec Pharmaceuticals
PremiumCompany Announcements
Fennec Pharmaceuticals Directors Elected Confidently
PremiumPress Releases
Fennec Announces Results of Annual Meeting
Bulls Say, Bears Say
Bulls Say
Financial PerformanceFENC reported 1Q24 results with a net income of $12.8MM and recorded Pedmark net revenue of $25.4MM, which included $18MM in licensing revenue from the Norgine transaction.
Market ExclusivityPedmarqsi has a Pediatric-Use Marketing Authorization, giving it a 10-year exclusivity in the EU.
Market ExpansionPedmark was included in the NCCN guidelines for AYA Oncology, which could broaden the opportunity to another ~30K in the US alone.
Bears Say
Market ChallengesPedmark uptake is facing challenges including confusion with the J-code, unlawful compounding, and the need to extend hours of infusion centers.
Product LaunchThe pediatric launch in the academic setting has slowed down due to a larger number of hospitals using compounded STS instead of Pedmark.
Sales PerformanceNet US Pedmark sales were below expectations, representing a -23.8% quarter-over-quarter growth.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
FENC FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was $5.66 and its highest was $11.92 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Currently, no data Available
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is Aug 09, 2024 which is in 17 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on May 14, 2024. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of -$0.058 by $0.468.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is -$0.02.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 27,322,142 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of $0.41 in its last earnings report, beating expectations of -$0.058. Following the earnings report the stock price went down -26.747%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in FENC
---
Fennec Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.00 (173.97% Upside)
$18.00 (173.97% Upside)
Blogger Sentiment
Neutral
FENC Sentiment 50%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.78%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
217.09%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
---
FENC Earnings Call
Q1 2024
0:00 / 0:00
---
FENC Stock 12 Month Forecast
Average Price Target
$18.00
▲(173.97% Upside)
Technical Analysis
Cidara Therapeutics
―
Adverum Biotechnologies
―
Revance Therapeutics
―
Arvinas Holding Company
―
Best Analysts Covering FENC
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
-7.17%
reiterated a buy rating 2 months ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -7.17% per trade.
---